CANAKINUMAB and DRUG INEFFECTIVE

Overview

DRUG INEFFECTIVE is the #3 most commonly reported adverse reaction for CANAKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,189 FDA adverse event reports linking CANAKINUMAB to DRUG INEFFECTIVE. This represents approximately 4.6% of all 25,877 adverse event reports for this drug.

Patients taking CANAKINUMAB who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DRUG INEFFECTIVE1,189 of 25,877 reports

DRUG INEFFECTIVE is moderately reported among CANAKINUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of CANAKINUMAB

In addition to drug ineffective, the following adverse reactions have been reported for CANAKINUMAB:

PYREXIA — 1,405 reports
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION — 1,242 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION — 953 reports
PAIN — 934 reports
CONDITION AGGRAVATED — 841 reports
MALAISE — 714 reports
OFF LABEL USE — 679 reports
ARTHRALGIA — 605 reports
RASH — 558 reports
INCORRECT DOSE ADMINISTERED — 502 reports

Other Drugs Associated with DRUG INEFFECTIVE

The following drugs have also been linked to drug ineffective in FDA adverse event reports:

0XYGEN ABACAVIR SULFATE ABATACEPT ABEMACICLIB ABIRATERONE ACETATE ACETAMINOPHEN ACETAMINOPHEN 500 MG ACETAMINOPHEN 500MG ACETAMINOPHEN AND CODEINE ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN AND IBUPROFEN ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, ASPIRIN, AND CAFFEINE ACETAMINOPHEN, ASPIRIN, CAFFEINE ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE ACETAMINOPHEN, CAFFEINE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE

Does CANAKINUMAB cause DRUG INEFFECTIVE?

DRUG INEFFECTIVE has been reported as an adverse event in 1,189 FDA reports for CANAKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DRUG INEFFECTIVE with CANAKINUMAB?

DRUG INEFFECTIVE accounts for approximately 4.6% of all adverse event reports for CANAKINUMAB, making it one of the most commonly reported side effect.

What should I do if I experience DRUG INEFFECTIVE while taking CANAKINUMAB?

If you experience drug ineffective while taking CANAKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.